The proper selection of high-performing study sites and investigators is paramount to a successful patient accrual effort. But many study sponsors have fallen into a common trap: they assume that more sites and more Investigators will result in faster patient accrual. This is especially true if a CRO is involved in the site/investigator selection process. However, this is most often not the case.
Consider this real-world example:

• A Phase III clinical trial in cancer has been enrolling patients for more than five years.
• 715 patients have been registered to the protocol.
• 234 study sites have activated the protocol.
• Only 27.4% of study sites (64/234) that have activated the protocol have registered as a patient.
• 72.6% of study sites (170/234) that have activated the protocol have NOT registered as a patient.
• The top 21 study sites (8.9%) are responsible for 80% of the accrual number.

It’s important to reiterate: 8.9% of sites that activated the protocol were responsible for 80% of patient accrual.

Through a variety of proprietary data, methods and research, Accrual Solutions helps study sponsors identify the study sites and investigators that are most likely to register an appropriate number of patients to a clinical trial protocol. Our objective approach differs from that of the typical CRO because we endeavor to limit, not maximize the total number of participating study sites and investigators. This can substantially improve the timeliness and budgetary efficiency of your patient accrual effort.